Results 21 to 30 of about 21,209 (213)

Could osteoprotegerin serve as a marker of metabolic syndrome?

Current Issues in Pharmacy and Medical Sciences, 2013
There has been a dramatic increase in the worldwide prevalence of obesity, which is associated with the development of several chronic diseases such as metabolic syndrome, type 2 diabetes and cardiovascular diseases.
Anna Maria Dąbrowska, Jerzy S. Tarach, Beata Wojtysiak-Duma, Arleta Malecha-Jędraszek, Anna Toruń-Jurkowska, Janusz Kudlicki, Helena Donica   +6 more
doaj   +1 more source

Serum Osteoprotegerin Level Is Negatively Associated with Bone Mineral Density in Patients Undergoing Maintenance Hemodialysis

Medicina, 2021
Background and Objectives: Osteoprotegerin (OPG), a potent osteoclast activation inhibitor, decreases bone resorption and plays a role in mediating bone mineral density (BMD).
Chia-Wen Lu, Chih-Hsien Wang, Bang-Gee Hsu, Jen-Pi Tsai   +3 more
doaj   +1 more source

Risk Factors Associated With Altered Circulating MicroRNA‐125b and Their Influences on Uremic Vascular Calcification Among Patients With End‐Stage Renal Disease

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background MicroRNA‐125b (miR‐125b) has been shown to regulate vascular calcification (VC), and serum miR‐125b levels are a potential biomarker for estimating the risk of uremic VC status.
Chia‐Ter Chao, Tzu‐Hang Yuan, Hsiang‐Yuan Yeh, Hsuan‐Yu Chen, Jenq‐Wen Huang, Huei‐Wen Chen   +5 more
doaj   +1 more source

Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
Background Elevated levels of osteoprotegerin, a secreted tumor necrosis factor–related molecule, might be associated with adverse outcomes in patients with coronary artery disease. We measured plasma osteoprotegerin concentrations on hospital admission,
Thor Ueland, Axel Åkerblom, Tatevik Ghukasyan, Annika E. Michelsen, Pål Aukrust, Richard C. Becker, Maria Bertilsson, Anders Himmelmann, Stefan K. James, Agneta Siegbahn, Robert F. Storey, Frederic Kontny, Lars Wallentin   +12 more
doaj   +1 more source

Impact of Alirocumab on Release Markers of Atherosclerotic Plaque Vulnerability in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque

Medicina, 2022
Background and Objectives: Atherosclerosis is a disease in the pathogenesis of which plasma factors apart from elevated cholesterol levels play a keyrole. Such factors include osteopontin (OPN), osteoprotegerin (OPG), and metalloproteinases (MMPs), which
Michał Kosowski, Marcin Basiak, Marcin Hachuła, Bogusław Okopień   +3 more
doaj   +1 more source

Relationship between serum osteoprotegerin and vascular calcifications in hemodialysis patients

The Egyptian Heart Journal, 2017
Background: Uremia is a vasculopathic process, and both cardiac calcification and vascular calcification seen from the early stages of chronic kidney disease.
Tarek Z. El Baz, Osama A. Khamis, Amal El-Shehaby, Hussein Chahine, Ahmad Alaa Al-Din Ahmed, Mostafa A. Alsawasany   +5 more
doaj   +1 more source

Beyond the Microbial Hypothesis: Shared Genetic, Osteoimmune and Vascular Mechanisms in the Oral-Brain Axis Linking Periodontitis and Alzheimer's Disease. [PDF]

Eur J Neurosci
Periodontitis is linked to Alzheimer's disease (AD) beyond the microbial hypothesis. This review reframes the oral–brain axis as an osteoimmune and vascular problem: The OPG/RANKL system acts as a bone–brain interface in which elevated OPG may limit neuroprotective RANKL, and circulating endocan provides a shared, treatment‐responsive vascular ...
Kabbashi S, Ahmed M, Chetty M.
europepmc   +2 more sources

Endogenous Calcification Inhibitors in the Prevention of Vascular Calcification: A Consensus Statement From the COST Action EuroSoftCalcNet

Frontiers in Cardiovascular Medicine, 2019
The physicochemical deposition of calcium-phosphate in the arterial wall is prevented by calcification inhibitors. Studies in cohorts of patients with rare genetic diseases have shed light on the consequences of loss-of-function mutations for different ...
Magnus Bäck, Tamas Aranyi, M. Leonor Cancela, Miguel Carracedo, Natércia Conceição, Georges Leftheriotis, Vicky Macrae, Ludovic Martin, Yvonne Nitschke, Andreas Pasch, Daniela Quaglino, Frank Rutsch, Catherine Shanahan, Victor Sorribas, Flora Szeri, Flora Szeri, Pedro Valdivielso, Olivier Vanakker, Hervé Kempf   +18 more
doaj   +1 more source

Osteoprotegerin Is more than a Possible Serum Marker in Liver Fibrosis: A Study into Its Function in Human and Murine Liver

Pharmaceutics, 2020
Osteoprotegerin (OPG) serum levels are associated with liver fibrogenesis and have been proposed as a biomarker for diagnosis. However, the source and role of OPG in liver fibrosis are unknown, as is the question of whether OPG expression responds to ...
Adhyatmika Adhyatmika, Leonie Beljaars, Kurnia S. S. Putri, Habibie Habibie, Carian E. Boorsma, Catharina Reker-Smit, Theerut Luangmonkong, Burak Guney, Axel Haak, Keri A. Mangnus, Eduard Post, Klaas Poelstra, Kim Ravnskjaer, Peter Olinga, Barbro N. Melgert   +14 more
doaj   +1 more source

Therapeutic implications of osteoprotegerin

Cancer Cell International, 2009
Osteoprotegerin (OPG), a member of the tumor necrosis factor (TNF) receptor superfamily, contributes determinatively to the bone remodeling as well as to the pathogenetic mechanism of bone malignancies and disorders of mineral metabolism. There is additional evidence that OPG can promote cell survival by inhibiting TNF-related apoptosis-inducing ligand
Fili, S., Karalaki, M., Schaller, B.
openaire   +4 more sources